Skip to main content

Additional Articles by the Authors

Todd Williamson, PhD, MSc
Rajesh Kamalakar, MS
Augustina Ogbonnaya, MPH
Erin A. Zagadailov, PharmD, MS
Michael Eaddy, PharmD, PhD
Charlie Kreilick, MBA
Jeffrey T. Guptill, MD, MA, MHS; M. Chris Runken, PharmD; Michael Eaddy, PharmD, PhD; Orsolya Lunacsek, PhD; Rupali M. Fuldeore, MS
Enhanced Understanding and Management of Rare Diseases Can Reduce Costs, Improve Clinical Outcomes
James T. Kenney, RPh, MBA
Todd Williamson, PhD, MSc; Wendy Y. Cheng, MPhil, MPH; Nora McCormick, MSc; Francis Vekeman, MA
There’s Room for Improvement in Rosacea Treatment
Gary M. Owens, MD
Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields, PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD
A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy
Gary Branning, MBA
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
A Teachable Moment in Health Benefits Design
Assessing the Value of Patient-Reported Outcomes
We Need More Research on True Value-Based Benefit Design that Will Improve Outcomes and Control Costs
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?

Results 1 - 9 of 9